title: Uncoupling protein 2 involved in protection of glucagon-like peptide 2 in small intestine with ischemia-reperfusion injury in mice.
abstract: Glucagon-like peptide 2 (GLP-2) is an intestinal epithelium-specific growth factor. However, its protective effects and related mechanism on the small intestine injured by ischemia-reperfusion (I/R) in mice remain unclear. This study aimed to reveal the effects of GLP-2 and its functional relationship with uncoupling protein 2 (UCP2) on the small intestine after I/R injury in mice. Male Balb/c mice were given GLP-2 (250 microg/kg/day, ip) for 3 days and underwent 30 min of superior mesenteric artery occlusion followed by 1 hr of reperfusion on day 4. Histological damage, bacterial translocation, diamine oxidase, and malondialdehyde level were assessed, and UCP2 expression was measured by immunohistochemistry and Western blot. GLP-2 attenuated the intestinal histological damage caused by I/R and increased the villous height by 28% and the crypt depth by 10%, respectively. Compared to the I/R group, diamine oxidase activity was increased, the incidence of bacterial translocation and malondialdehyde level were decreased, and UCP2 expression was increased in GLP-2-treated mice. GLP-2 protected the small intestine from I/R injury and increased UCP2 expression. These results suggested that effects of GLP-2 should be related to the upregulation of mitochondrial UCP2, which antagonized reactive oxygen species production.
authors.affiliation: Department of Physiology, Dalian Medical University, Dalian 116027, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Guan
authors.forename: Dezheng
authors.initials: D
authors.lastname: Gong
authors.forename: Nan
authors.initials: N
authors.lastname: Tian
authors.forename: Yuan
authors.initials: Y
authors.lastname: Zou
mesh_terms: D000818:Animals; D001707:Biopsy, Needle; D015153:Blotting, Western; D004195:Disease Models, Animal; D053767:Glucagon-Like Peptide 2; D004763:Glucagon-Like Peptides; D007150:Immunohistochemistry; D007274:Injections, Intraperitoneal; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology; D007421:Intestine, Small / Q000187:drug effects / Q000473:pathology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010455:Peptides / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology*; D011336:Probability; D011897:Random Allocation; D012016:Reference Values; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology*; D012680:Sensitivity and Specificity
chemical_list: D053767:Glucagon-Like Peptide 2; D010455:Peptides; D004763:Glucagon-Like Peptides